Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease

Small Volume ◽

Randomized Study ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps257 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS257-TPS257 ◽

Cited By ~ 4

Author(s):

J. D. Hainsworth ◽

T. M. Numnum ◽

G. G. Rao

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer

Cancer ◽

10.1002/cncr.22466 ◽

2007 ◽

Vol 109 (4) ◽

pp. 692-702 ◽

Cited By ~ 96

Author(s):

Laurie Elit ◽

Thomas K. Oliver ◽

Allan Covens ◽

Janice Kwon ◽

Michael Fung-Kee Fung ◽

...

Keyword(s):

Ovarian Cancer ◽

Intraperitoneal Chemotherapy ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

Cancer Medicine ◽

10.1002/cam4.376 ◽

2014 ◽

Vol 4 (5) ◽

pp. 673-681 ◽

Cited By ~ 30

Author(s):

John D. Hainsworth ◽

Dana S. Thompson ◽

John A. Bismayer ◽

Victor G. Gian ◽

William M. Merritt ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment ◽

Research Institute

Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study

International Journal of Gynecological Cancer ◽

10.1046/j.1525-1438.2003.13039.x ◽

2003 ◽

Vol 13 (2) ◽

pp. 130-137 ◽

Cited By ~ 9

Author(s):

T. Bauknecht ◽

A. Hefti ◽

G. Morack ◽

C. Villena-Heinsen ◽

D. Wallwiener ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort

The Pharmacogenomics Journal ◽

10.1038/s41397-018-0056-y ◽

2018 ◽

Vol 19 (1) ◽

pp. 25-32

Author(s):

Ricardo Pinto ◽

Joana Assis ◽

Augusto Nogueira ◽

Carina Pereira ◽

Sara Coelho ◽

...

Keyword(s):

Ovarian Cancer ◽

Treatment Outcome ◽

Line Treatment ◽

First Line ◽

First Line Treatment ◽

Independent Cohort

P168 Influence of first-line treatment for epithelial ovarian cancer on the immune system

10.1136/ijgc-2019-esgo.229 ◽

2019 ◽

Author(s):

T Baert ◽

C Landolfo ◽

J Ceusters ◽

G Thirion ◽

A Van Hoylandt ◽

...

Keyword(s):

Ovarian Cancer ◽

Immune System ◽

Line Treatment ◽

First Line ◽

Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.07.050 ◽

2020 ◽

Vol 159 (2) ◽

pp. e14

Author(s):

Courtney Alexis Penn ◽

Melissa Spring Wong ◽

Christine Walsh

Keyword(s):

United States ◽

Ovarian Cancer ◽

Cost Effectiveness ◽

The United States ◽

Line Treatment ◽

First Line ◽

Mutation Status ◽

Primary Epithelial Ovarian Cancer ◽

Weekly topotecan as first-line treatment for recurrent or persistent epithelial ovarian cancer (EOC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.5111 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5111-5111

Author(s):

T. Safra ◽

J. Menczer ◽

M. Inbar ◽

E. En-Shem ◽

M. Glezerman ◽

...

Keyword(s):

Ovarian Cancer ◽

Line Treatment ◽

First Line ◽

9318 POSTER Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma

European Journal of Cancer ◽

10.1016/s0959-8049(11)72527-8 ◽

2011 ◽

Vol 47 ◽

pp. S657-S658

Author(s):

C. Robert ◽

L. Thomas ◽

C. Garbe ◽

C. Lebbe ◽

J.F. Baurain ◽

...

Keyword(s):

Randomized Study ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Unresectable Stage ◽

Faculty of 1000 evaluation for Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718148939.793486580 ◽

2013 ◽

Author(s):

David Kushner ◽

Erin Medlin

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Line Treatment ◽

First Line ◽